Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya

Last updated: May 1, 2025
Sponsor: Oyster Point Pharma, Inc.
Overall Status: Completed

Phase

4

Condition

Dry Eye Disease

Dry Eyes

Sjogren's Syndrome

Treatment

Nasal Guide

Clinical Study ID

NCT05918406
OPP-009
  • Ages > 18
  • All Genders

Study Summary

The objective of this study is to determine the safety of the nasal guide when utilized to aid in the administration of Tyrvaya (varenicline solution 0.03mg) Nasal Spray

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Be at least 18 years of age

  2. Have provided verbal and written informed consent

  3. Willing to comply with all study related visits and procedures

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Nasal Guide
Phase: 4
Study Start date:
June 14, 2023
Estimated Completion Date:
August 18, 2023

Study Description

Protocol OPP-009 is a single center, open-label study to evaluate the safety of the nasal guide during administration of Tyrvaya (varenicline solution 0.03mg) Nasal Spray. Approximately 30 subjects at least 18 years of age will be enrolled at one clinical study site and will receive the nasal guide for use with the administration of Tyrvaya for 7 days.

Connect with a study center

  • United States, New Jersey

    Edison, New Jersey 08820
    United States

    Site Not Available

  • United States, New Jersey

    Woodland Park, New Jersey 07424
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.